



2corex

**Because cancer patients are individuals**

Because cancer patients are individuals



## Introducing 2cureX

### Company in short

2cureX was founded in 2006 with the vision of improving treatment efficiency of cancer patients. From the start, 2cureX has been in close collaboration with key cancer hospitals in the Copenhagen area and beyond. This has since been expanded to include hospitals in Germany and The United Kingdom.

### Successful collaboration partner

2cureX initiated successfully multiple collaborations with both commercial and academic partners and has since its inception raised over €11 million in both national and international grants and private investments.

### Unique Technology

2cureX's proprietary technology is called IndiTreat®, which has been developed and tested in more than 900 patients with promising results.

### Business model with attractive risk profile

2cureX will offer IndiTreat® to cancer hospitals and clinics as a service. 2cureX is present at major cancer hospitals in Germany, The United Kingdom and Denmark. 2cureX has an attractive risk-profile for investors due to a unique functional test, that strongholds in major European hospitals and close to launch in a highly attractive market.



## Unique Proprietary Technology

### IndiTreat®

2cureX has developed the IndiTreat® test, which helps doctors, and other health professionals determine the optimal treatment for the individual cancer patients through a fast, effective and comprehensive approach.

### Micro-Tumors

IndiTreat® uses a small tumor sample from patients to create a large number of 3-dimensional Micro-Tumors. Using these Micro-Tumors, IndiTreat® tests all available chemotherapies and experimental treatments. IndiTreat® delivers results within 14 days of sampling, enabling rapid selection of the optimal treatment. This improves treatment and cost efficiency.

### Individualized Treatment



IndiTreat® is designed to optimize the medical treatment for cancer patients.

### IndiTreat® is in Clinical Validation

IndiTreat® is currently being clinically validated in a multi-national clinical trial in the Nordics, Germany and the UK.

Patients are being tested today with IndiTreat® to design their individual treatment

### IndiTreat® derived Micro-Tumor



Effective treatment found

## IndiTreat®



### IndiTreat®

Identifies the treatment that most efficiently kills your tumor



### IndiTreat®

Generates from a small tumor sample 1000's of 3D Micro-Tumors and exposes them to available drug therapies



### IndiTreat®

uniquely complements existing oncology care procedures



## Attractive Investment profile

### 2cureX product pipeline

2cureX Areas of interest	Product Candidate	Discovery State	Preclinical Development	Clinical Validation	Product Launch
Colorectal Cancer	IndiTreat® - CRC				
Ovarian Cancer	IndiTreat® - OVA				
Other solid Tumors	IndiTreat®				
Immuno Oncology	IndiTreat® - I/O				



IndiTreat® market Launch is planned for 2020



Sound cash position  
Successful IPO + EU grant  
Horizon2020 program



2cureX is currently clinically testing  
IndiTreat® in 3 major EU-Cancer  
Markets



[www.2curex.com](http://www.2curex.com)

## **2cureX AB**

Info@2curex.com  
www.2curex.com

**Market:** Nasdaq First North, Stockholm  
**Ticker:** 2CUREX.ST

 **Twitter:** @2cureX

 **LinkedIn:** 2cureX